Sana Biotechnology employs a two-part strategy to make transplanted cells invisible to the immune system. First, they engineer the cells to remove their unique identifying "fingerprint." Second, they overexpress a protein called CD47, which acts as a "don't eat me" signal to another part of the immune system that hunts for cells lacking a fingerprint.

While Natural Killer (NK) cells themselves are too large to cross the blood-brain barrier, the nanoscale extracellular vesicles (EVs) they produce can. This allows Avenco to harness the therapeutic potential of NK cells for neurodegenerative diseases by delivering their active cargo directly into the brain, solving a fundamental delivery challenge.

Unlike one-to-one autologous therapies, an allogeneic approach allows the creation of a master cell bank from a single donor. This bank can then reproduce enough cells to treat millions of patients, making it a truly off-the-shelf, scalable pharmaceutical.

Advanced cell therapy isn't just about replacing lost cells. Transplanted, genetically engineered cells can be programmed to produce and secrete therapeutics locally. This turns them into a delivery platform that solves the critical challenge of the blood-brain barrier for large molecules.

Early data from an in vivo CAR-T therapy suggests a paradigm shift is possible. By engineering T-cells directly inside the patient with a simple infusion, this approach could eliminate the need for leukapheresis and external manufacturing, completely disrupting the current cell therapy model.

The HLAG protein on placental tissue acts as a natural "off-switch" for the maternal immune system, preventing rejection of the embryo. This inherent immune privilege makes these cells ideal for allogeneic "off-the-shelf" therapies that can be given to any patient without requiring a genetic match.

Unlike many cell therapies, Rion's platelet-derived exosomes are devoid of the self/non-self surface markers that trigger immune rejection. This "immune privilege" is a critical biological advantage, allowing the product to be used as a universal, off-the-shelf therapy for any patient without needing donor matching.

Allogeneic ("off-the-shelf") CAR-T isn't just a cheaper alternative to autologous therapy; it's a medical necessity for certain cancers. In T-cell leukemia, the patient's own T-cells are cancerous and cannot be used to create a treatment. Therefore, therapy derived from a healthy donor is the only possible path forward for these patients.

CEO Lance Baldo suggests that gene therapy in the eye is uniquely positioned for success. As an encapsulated organ with "immune privilege," the eye reduces risks like hepatotoxicity seen in systemic therapies. This creates a safer environment to generate learnings that can then be applied to advance gene therapies for other organs.